Mizuho Medy Co., Ltd. (4595) AI Stock Analysis

• Market Cap: ¥31.45B
• Dividend Yield: 6.74%
• Average Volume (3M): 67.85K
• Price to Earnings (P/E): 9.5
• Beta (1Y): 0.38
• Revenue Growth: -3.11%
• EPS Growth: -13.09%
• Country: JP
• Employees: 187
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 12.78
• Shares Outstanding: 19,051,200
• 10 Day Avg. Volume: 83,300
• 30 Day Avg. Volume: 67,853
• PEG Ratio: -250.24
• Price to Book (P/B): 1.65
• Price to Sales (P/S): 2.50
• P/FCF Ratio: 9.38
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 71 Outperform
• Price Target: ―

Overall, Mizuho Medy Co., Ltd. exhibits strong financial performance with excellent balance sheet strength and profitability. Despite the positive valuation metrics, technical indicators suggest a bearish trend, which could pose a risk. The stock's low P/E ratio and high dividend yield are attractive, but the current price trends indicate caution.

Mizuho Medy Co., Ltd. Business Overview & Revenue Model

Company Description

Mizuho Medy Co., Ltd. (4595) is a Japanese company primarily engaged in the development, manufacturing, and sale of medical devices and healthcare-related products. The company focuses on providing innovative solutions in the medical industry, catering to the needs of healthcare professionals and institutions. Its product lineup includes a variety of medical devices, health monitoring equipment, and related consumables that are used in various medical settings.

How the Company Makes Money

Mizuho Medy Co., Ltd. generates revenue through the sale of its medical devices and healthcare products. The company targets hospitals, clinics, and other healthcare facilities as its primary customer base, supplying them with essential medical equipment and consumables. Revenue is driven by the continuous demand for high-quality and reliable medical devices, which are crucial for patient care and medical procedures. The company may also engage in partnerships or collaborations with other healthcare organizations to expand its product offerings and reach a wider market. Additionally, Mizuho Medy Co., Ltd. may benefit from ongoing advancements in medical technology, which can lead to the development of new products and open up additional revenue streams.

Mizuho Medy Co., Ltd. Financial Statement Overview

Summary

Mizuho Medy Co., Ltd. demonstrates strong financial health with robust profitability, excellent balance sheet strength, and effective cash flow management. The income statement shows strong profitability with consistent gross and net profit margins. The balance sheet is very strong with zero debt and a high equity ratio, reflecting excellent financial stability. Cash flow indicates positive free cash flow, though it declined from 2023 to 2024.

Income Statement

The income statement shows strong profitability with consistent gross and net profit margins. Gross profit margin remained high at approximately 70.7% in 2024, and net profit margin was also strong at 33.0%. Revenue grew by 4.0% from 2023 to 2024, indicating steady growth. EBIT and EBITDA margins were robust at 43.0% and 45.0%, respectively, highlighting efficient operations.

Balance Sheet

The balance sheet is very strong with zero debt and a high equity ratio of 83.7% in 2024, reflecting excellent financial stability. Return on Equity (ROE) was impressive at 21.7%, showing effective use of shareholder funds. The high level of cash and short-term investments enhances liquidity and risk resilience.

Cash Flow

The cash flow statement indicates positive free cash flow, though it declined by 18.1% from 2023 to 2024. The operating cash flow to net income ratio was 0.89, indicating good cash generation from operations. However, the free cash flow to net income ratio also suggests a solid conversion of profits into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	10.74B	11.43B	10.99B	17.58B	12.89B	4.20B
Gross Profit	7.63B	8.08B	8.07B	14.10B	9.65B	2.76B
EBITDA	4.71B	5.15B	5.35B	11.23B	7.00B	611.11M
Net Income	3.30B	3.77B	3.77B	7.84B	4.82B	306.35M
Balance Sheet
Total Assets	19.73B	20.73B	18.95B	19.10B	12.19B	6.05B
Cash, Cash Equivalents and Short-Term Investments	12.37B	11.25B	10.13B	8.70B	4.33B	54.31M
Total Debt	0.00	0.00	0.00	0.00	0.00	593.34M
Total Liabilities	2.50B	3.38B	3.27B	4.82B	4.16B	2.27B
Stockholders Equity	17.23B	17.35B	15.68B	14.28B	8.03B	3.78B
Cash Flow
Free Cash Flow	0.00	3.05B	3.72B	5.99B	5.44B	198.36M
Operating Cash Flow	0.00	3.35B	3.99B	6.17B	5.60B	295.42M
Investing Cash Flow	0.00	-307.00M	-270.45M	-1.55B	-159.74M	-97.32M
Financing Cash Flow	0.00	-2.09B	-2.38B	-1.57B	-1.16B	-361.10M

Mizuho Medy Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1651.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4595, the sentiment is Positive. The current price of 1651 is above the 20-day moving average (MA) of 1619.65, above the 50-day MA of 1565.46, and above the 200-day MA of 1471.22, indicating a bullish trend. The MACD of 24.62 indicates Negative momentum. The RSI at 70.20 is Negative, neither overbought nor oversold. The STOCH value of 82.46 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4595.

Mizuho Medy Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4595	71 Outperform	¥31.45B	9.52	―	6.74%	-3.11%	-13.09%
4569	69 Neutral	¥76.96B	8.15	―	3.60%	9.83%	86.18%
4886	68 Neutral	¥58.31B	12.25	―	2.42%	6.23%	-31.45%
4577	63 Neutral	¥35.93B	19.04	―	4.41%	7.56%	-48.91%
4538	60 Neutral	¥19.07B	6.46	―	3.77%	8.71%	-325.91%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%